idea-010 · business case

Who pays, from which budget, how much, and 2-4 commercial routes to first revenue — every figure below traces to a copied claim or a declared assumption, and the routes are laid out unranked. Choosing a commercial strategy is a Tier 3 act, so this page presents options and stops.

Single-use strip and handheld meter measuring potassium and creatinine from a fingerstick drop, with on-strip hemolysis rejection, for RAASi dose titration in outpatient heart-failure and CKD clinics — business case

Intended use: For the quantitative measurement of potassium and creatinine in fingerstick capillary whole blood by trained healthcare personnel at the point of care in outpatient clinics, as an aid in monitoring adults with chronic heart failure or chronic kidney disease during initiation and dose titration of renin-angiotensin-aldosterone system inhibitors; not for use in emergency, critical-care, or dialysis-adequacy decision-making.

Who pays

Two cheques, written by two different parties, and the business only works if the second one is larger than the first. Since the last build the second cheque has a known size for one payer; the first still has no known size at all.

Writes the cheque for the device: the outpatient heart-failure or nephrology clinic, buying the meter and strips directly. Nothing in the candidate establishes that; it is on record as a proposition the Verifier attempted and could not settle, because purchasing channel is behaviour and has no connector claim 44unconfirmed. The linked dossier treats prescriber, operator, purchaser, payer and patient as five separate parties with different incentives, and records all five as unsearched.
Writes the cheque for the test: the patient's payer, per test, through the Clinical Laboratory Fee Schedule and not the Physician Fee Schedule. That is now a verified fact for Medicare fee-for-service: both codes are priced on the CLFS (clinical laboratory fee schedule), and neither carries a physician payment claim 14verified. Medicare Advantage (Medicare Advantage) and commercial payers were not checked, and the case assumes they pay at least the Medicare rate [assumption A3].
Out of which budget line: the clinic's point-of-care testing consumables line, meant to be recovered from the per-test lab payment. That only holds if the clinic is the party that bills and keeps the payment rather than the reference laboratory it sends to today claim 37unconfirmed, if potassium and creatinine from one strip are paid as two tests rather than one claim 38unconfirmed, and if the clinic is a physician-office site billing on its own CLIA (Clinical Laboratory Improvement Amendments) certificate rather than a hospital-owned department billing on the hospital's claim [assumption A2]. It also needs a CLIA Certificate of Waiver that the clinic holds or would obtain, plus willingness to carry the QC (quality control) and competency burden that comes with it claim 29unconfirmed.
Against which comparator: a venous draw sent to an outside laboratory, with the dose decision made after the result comes back. The monitoring cadence that would make an in-visit result worth having is taken from a guideline summary, not the guideline itself claim 21unconfirmed.
Stops buying instead: nothing is bought by the clinic today, because the send-out draw is billed by the reference laboratory. What the clinic gives up is a referral, and what it takes on is a test it must bill for itself. Whether the fingerstick replaces the titration draw or adds a second stick to it is unresolved claim 33unconfirmed. If the venous draw is still needed for other analytes, this is additive spend at every adopting clinic.

The chain's first link is still an assumption and its second is now half-known. Nobody has shown who buys the device. The verified CLFS rate shows what Medicare pays per test, but not whether the clinic keeps that payment, and not what running the test costs.

Reimbursement path

Six questions, each with its own evidence position and one basis. No score, no tier, no composite. Read the coverage line first.

#	Question	Finding	Basis
2a	Coding route — Cat I / Cat III / unlisted / HCPCS (Healthcare Common Procedure Coding System) II / none	Existing Category I laboratory codes, with no new code sought. Potassium 84132 and creatinine 82565 both exist and are priced on the CLFS claim 14verified. Whether a capillary fingerstick sample from this device sits inside those codes' descriptor wording is the question that matters here. That wording is AMA-licensed, is not reproduced here, and was not checked for either code claim 12unconfirmed. Billing from a waived-certificate site is said to need the QW modifier, which is also unchecked claim 13unconfirmed. `hcpcs 84132` returns unconfirmed because a Level I code cannot be found in the Level II file	claim 11unconfirmed
2b	Payment adequacy — does the rate clear a stated cost floor	The rate is known and no cost floor has been stated. Medicare CLFS national limitation amounts for 2026 are $4.76 for potassium and $5.12 for creatinine claim 14verified. That is $9.88 for the pair, if both are paid claim 38unconfirmed. Nothing in the file quantifies the other side: strip cost, meter amortisation, QC material and operator time. So whether the payment clears the cost is still open claim 36unconfirmed. The rates are Medicare fee-for-service only. The case assumes other payers pay at least as much [assumption A3]	claim 36unconfirmed
2c	Practice-expense headroom — does the PE portion cover the device	There is no practice-expense portion, by construction. Both codes carry PFS (physician fee schedule) procedure status X, a statutory exclusion from the definition of a physician service. That means no physician payment and no PE RVU (relative value unit) for the strip's cost to sit inside claim 14verified. The device can only be recovered from the CLFS lab payment in 2b	claim 14verified
2d	Site of care & bundling — office/facility differential, DRG or APC packaging	Office or hospital department is not settled, and bundling of the pair is unchecked. The verified Medicare carrier-file volume is almost entirely office/non-facility: 319,876 of 320,020 potassium services claim 16verified. That file carries no hospital-outpatient institutional claims, though, so it cannot say how many target clinics are hospital-owned departments. The case assumes a material share are physician offices [assumption A2]. `apc 84132` and `apc 82565` return unconfirmed because no OPPS Addendum B cache exists, so how the tests are treated in a hospital-outpatient setting was not checked. That is a tooling gap, not a finding. No DRG applies: the intended use is outpatient only. Whether two analytes from one specimen are paid separately is an NCCI question with no connector claim 38unconfirmed	[assumption A2]
2e	Coverage — has any payer agreed to pay for this indication	No payer has been shown to cover this indication, and no policy has been shown to restrict it. `coverage 84132` and `coverage 82565` both return refuted: no policy in the cached coverage file names either code. The file does not carry that result as a tag. The cache is the MCD billing-and-coding article export and carries no NCD (national coverage determination) text, and a no-policy result points the same way as the claim rather than against it claim 15unconfirmed. With no policy, claims go to case-by-case contractor adjudication. How often a titrating patient can be tested and still be paid is unknown	claim 15unconfirmed
2f	Ex-US pathway — DE NUB/G-DRG, UK NICE (National Institute for Health and Care Excellence)/OPCS-4	Permanently unconfirmed, and not because research is missing. `launch_jurisdiction:` is US, and no connector in this repo reaches a non-US payment system. For Germany, the case assumes an outpatient point-of-care test is paid within an existing statutory ambulatory laboratory fee position, so no new-method route is needed. NUB and G-DRG are inpatient and do not apply to this intended use. That is assumed, not checked [assumption A1]. The UK has no claim or assumption behind it in either direction	[assumption A1]

Pillars on verified claims: 1/6 · on assumptions: 2 · queued as research: 0

The other three (2a, 2b, 2e) rest on unconfirmed claims. Read the one verified pillar for what it says. It is 2c, and it is a negative: there is no practice-expense line to carry the device. Since the last build the rate in 2b and the volume in 2d have both become verified facts, but they are not what those rows turn on. 2b turns on cost, which nobody has stated. 2d turns on site of care, which the verified file cannot see. So the verified information on this page grew, and the verified pillar count grew by only the one row that answers no.

Three distinctions kept apart on purpose:

A code existing is not payment, and payment is not coverage. The codes exist and are priced (2a, 2b). No policy names them either way (2e). And whether this device fits the codes' descriptor wording is exactly the part this pipeline cannot read.
A packaged OPPS code or an inpatient DRG case pays the facility nothing extra. No DRG is in play. Whether a hospital-owned clinic would be paid separately for the test is unchecked, because apc has no cache. So it is an open question, not a clear one.
2f is permanently unconfirmed. It will not be settled by a further pass inside this repo.

Verdicts from checks that were run and came back unusable, stated as the spec asks:

python3 -m connectors cpt 84132 → unverifiable: "CPT (Current Procedural Terminology) descriptors are AMA-licensed and cannot be scraped or reproduced verbatim ... The code NUMBER is not barred".
python3 -m connectors hcpcs 84132 --jurisdiction US → unconfirmed: a Level I code, which the Level II file cannot answer for.
python3 -m connectors apc 84132 --jurisdiction US and apc 82565 → unconfirmed: "No local cache at data/opps_addendum_b.csv".
python3 -m connectors rvu 84132 --jurisdiction US and rvu 82565 → refuted: procedure status X, "there is no separate physician payment to fund a device out of". This is the finding behind 2c, and the file already carries it inside claim 14verified.

The money model

There is no market model for this candidate (knowledge-base/market-models/idea-010.md does not exist), so there is nothing to link. This case does not build the size in its place. The rows below are the unit economics the file can support, and each one says where its number comes from or that there is none. /market-model idea-010 is the cheaper next pass for the size question.

Line	Figure	Backing
Medicare FFS (fee-for-service) services, standalone potassium code 84132, national	320,020 services, of which 319,876 office/non-facility and 144 facility. This is a floor in one payer's fee-for-service carrier book, and it excludes potassium reported inside a panel and hospital-outpatient institutional claims. Not a market size, and mostly central-lab draws this device does not take	claim 16verified
Medicare FFS services, standalone creatinine code 82565, national	1,160,145 services, of which 1,160,036 office/non-facility and 109 facility. Same caveats	claim 16verified
Medicare CLFS payment per test, potassium 84132	$4.76, 2026 national limitation amount	claim 14verified
Medicare CLFS payment per test, creatinine 82565	$5.12, 2026 national limitation amount	claim 14verified
Medicare CLFS payment for the pair from one strip	$9.88, if both are paid separately, which is unchecked	claim 38unconfirmed
Medicare Advantage and commercial payment per test, relative to the CLFS	at or above the Medicare rate. Assumed, not checked	[assumption A3]
Clinic keeps the payment rather than the reference lab	not established	claim 37unconfirmed
Fully loaded in-office cost per paired test (strip, meter amortisation, QC, operator time) below the payment	not established. No cost figure appears anywhere in the file	claim 36unconfirmed
Net strip price to the clinic	none asserted. The Medicare ceiling for the pair is $9.88, and the floor (strip cost of goods) has no source	claim 17unconfirmed
Strip price set below the combined allowable with room for manufacturer margin	not established	claim 45unconfirmed
Manufacturer gross margin per strip	not established	claim 46unconfirmed
Meter price or placement cost to the clinic	not established	claim 47unconfirmed
In-visit paired tests per insourcing clinic per year	not established. National totals do not break down to a clinic	claim 48unconfirmed
Count of US HF and nephrology clinic sites sending potassium out today	not established. `market` returns unverifiable, and no licensed source has been shown to exist	claim 35unconfirmed
Share of such clinics insourcing within five years	10-20%, the Generator's own figure, over an uncounted denominator	claim 18unconfirmed
Share of insourcing clinics choosing this device over an incumbent point-of-care analyzer	not established	claim 49unconfirmed
Share of placements still running potassium in-house twelve months later (the revealed-behaviour twin of "would clinics switch")	a majority, assumed. Settled by reorder data, not by asking	[assumption A4]
Invalid-result rate per fingerstick attempt in ordinary clinic hands	not established. Bench work, no connector	claim 23unconfirmed

No revenue line and no composite dollar figure appear on this page, on purpose. Multiplying the Medicare service counts by the CLFS rates would give the Medicare fee-for-service spend on standalone potassium and creatinine tests, run almost entirely in central labs claim 16verified. That is not revenue this device could reach, and the candidate's own claim says it must never be read as a market size. Every row that would turn that spend into device revenue sits on an unconfirmed claim or an assumption.

What the verified rows do settle is a ceiling, not a price. Under Medicare fee-for-service, a clinic that pays more than $9.88 for the strip, meter share, QC and staff time behind one paired result loses money on every test it insources claim 14verified. That holds even if everything else in the table resolves in the device's favour claim 36unconfirmed.

Verdicts for the two claim types a business case is mostly made of, run for this build:

python3 -m connectors market "the US addressable market for a fingerstick potassium and creatinine strip in outpatient heart-failure and nephrology clinics" → unverifiable: "has no free, authoritative, machine-queryable source. Stays unconfirmed permanently unless a human attaches a licensed report".
python3 -m connectors adoption "outpatient heart-failure and nephrology prescribers will change a RAASi or MRA dose in-visit on a fingerstick potassium result rather than order a confirmatory venous draw" → unverifiable: "needs primary research ... Do NOT substitute a model's own estimate of stakeholder behaviour". This is the same question as claim 28unconfirmed.
python3 -m connectors adoption "outpatient heart-failure and nephrology clinics would buy a fingerstick potassium and creatinine strip meter instead of sending the test to an outside laboratory" → unverifiable, same detail. Its revealed-behaviour twin is carried as [assumption A4].

Checkable primitives re-run for this build rather than quoted: payment 84132 and payment 82565 → verified, procedures 84132 and procedures 82565 → verified, coverage 84132 and coverage 82565 → refuted (no policy names the code), rvu → refuted (status X), apc → unconfirmed (no cache), hcpcs 84132 → unconfirmed (Level I code). Each one reproduces what the candidate file records. icd was not used for population, because its cache is absent (icd N18.3 → unconfirmed).

Path to first revenue

First dollar comes from: a device sale to the first outpatient HF or nephrology clinic that buys the meter and strips claim 44unconfirmed. That is a sale, not a reimbursement event. The clinic's own CLFS payment arrives afterwards, and it caps what the clinic could ever pay per paired test claim 14verified.
What must exist first, each attributed:
- Clearance under two Class II (FDA device class II) generic types: potassium test system 21 CFR (Title 21 of the Code of Federal Regulations) 862.1600 claim 1verified and creatinine test system 21 CFR 862.1225 claim 2verified, with product codes CEM claim 3verified and CGL claim 4verified. Both identifications name plasma, serum or urine, and neither names capillary whole blood claim 1verified.
- A creatinine-channel predicate: K070068 (an FDA 510(k) clearance number), cleared for point-of-care use on capillary whole blood by health care professionals, with plasma-equivalent calibration claim 5verified.
- A potassium-channel predicate argument. The 30-year enumeration of both potassium product codes found no strip-and-fingerstick device. It did find cleared whole-blood point-of-care potassium systems (K200865, K042270), whose adequacy as predicates is an FDA (US Food and Drug Administration) judgment. It is a searched null, not a clear field claim 7unconfirmed.
- A CLIA waiver. FDA operates the Dual 510(k) (premarket notification) and CLIA Waiver by Application pathway and has issued a final guidance on it claim 8verified. What study package that guidance would require for this device has not been sized.
- The hemolysis channel has to work: capillary lysis must be detected and the potassium result suppressed claim 22unconfirmed at the free-hemoglobin level that actually biases potassium claim 40unconfirmed, across the HF/CKD hematocrit range claim 41unconfirmed and a commercial shelf life claim 42unconfirmed, with an invalid-result rate low enough to use claim 23unconfirmed, and reviewed inside the device's own submission claim 43unconfirmed.
- An FTO (freedom to operate) position. No patent has been searched, in art actively practised by the incumbents claim 25unconfirmed.
Calendar to first dollar: not established. The file asserts no month figure, because any figure would be invented claim 26unconfirmed, claim 50unconfirmed.
Capital to first dollar: not established, for the same reason claim 51unconfirmed.
Lag from a clinic's purchase to its first paid CLFS claim: not established claim 52unconfirmed.

Routes

Four routes. None is ranked or weighted, and they are laid out in the order the candidate file raises them. All four sit on one claim no connector reaches: whether a fingerstick hemolysis channel can tell a biased sample from a clean one claim 22unconfirmed. That is a fact about the file, not a ranking.

Route A — Sell strip and meter to physician-office clinics, billed on the CLFS

The model the candidate itself describes. A device company sells to outpatient HF and nephrology clinics, and they bill 84132 and 82565 themselves claim 14verified.

Requires: clearance of both channels and a CLIA waiver claim 5verified, claim 7unconfirmed, claim 8verified; clinics that are physician-office sites billing on their own certificate [assumption A2] and willing to carry the waiver burden claim 29unconfirmed; the clinic keeping the payment claim 37unconfirmed for two separately paid tests claim 38unconfirmed; and a purchaser who is the clinic itself claim 44unconfirmed.
Costs: calendar claim 50unconfirmed and capital claim 51unconfirmed to first dollar, the claims-cycle lag before a clinic is paid claim 52unconfirmed, strip margin claim 46unconfirmed, and meter placement claim 47unconfirmed. No figure for any of them exists in the file.
Killed by: the fully loaded in-office cost of one paired result coming in above what the clinic is paid for it. That means claim 36unconfirmed resolving false against the verified Medicare ceiling claim 14verified and against what other payers pay [assumption A3]. At that point no clinic has a reason to buy.

Route B — License the hemolysis module into an incumbent point-of-care analyzer

Sell the differentiator rather than the form factor. The hemolysis detect-and-suppress logic is qualified as an add-on to a platform that already has a cleared whole-blood point-of-care potassium channel. The Piccolo potassium clearance is the verified half of claim 10unconfirmed, and the incumbent field is named in claim 27unconfirmed.

Requires: the module detecting free hemoglobin at the level that biases potassium claim 40unconfirmed with a workable invalid-result rate claim 23unconfirmed; the add-on qualifying without a new full 510(k) for the host device claim 53unconfirmed; an FTO position on hemolysis-flagging art specifically claim 25unconfirmed; and a moat that is filed or filable IP (intellectual property) rather than asserted claim 24unconfirmed.
Costs: bench validation against the host analyzer and a regulatory scoping opinion. This route has no strip manufacturing and no clinic channel to build, and no figure for either cost exists in the file claim 53unconfirmed.
Killed by: bench data showing the channel cannot tell a biased sample from a clean one at the threshold that matters, which is claim 22unconfirmed resolving false. That leaves nothing to license.

Route C — Launch the OTC home-use version first

Go straight to at-home RAASi titration, which the candidate's frontmatter calls the biggest commercial lever, instead of treating home use as a second submission.

Requires: the same two-channel regulatory base as Route A claim 1verified, claim 2verified, claim 5verified; a cleared fingertip home-use format analog on the same manufacturer's platform family, which exists but is a glucose/ketone meter rather than a potassium or creatinine predicate claim 6verified; patients accepting the fingerstick claim 30unconfirmed; and lay users getting an adequate drop without supervision, a harder version of claim 32unconfirmed.
Costs: a lay-comprehension and untrained-operator study package on top of the professional track claim 54unconfirmed, plus the same calendar and capital unknowns as Route A claim 50unconfirmed, claim 51unconfirmed.
Killed by: human-factors testing showing lay users cannot reliably get a valid drop, or cannot act correctly on a suppressed result without a clinician. That is claim 54unconfirmed failing before a submission is possible.

Route D — Sell a monitoring service to health systems, priced against RAASi discontinuation

Step around the per-test CLFS margin by selling in-visit monitoring to health systems or HF/CKD programmes, priced against the cost of patients coming off RAASi or MRA therapy rather than against a lab fee schedule.

Requires: a measured link between potassium-monitoring frequency and RAASi/MRA continuation. The file's discontinuation figures come from a search summary with no primary paper read claim 20unconfirmed. The linked dossier records that the studies isolating hyperkalemia as the reason for stopping are non-US. The route also needs clinicians who act on an in-visit result rather than deferring to a venous draw claim 28unconfirmed.
Costs: a health-system study or claims analysis establishing that link claim 55unconfirmed, on top of the regulatory base in Route A claim 50unconfirmed, claim 51unconfirmed.
Killed by: the study coming back with no measurable link between monitoring frequency and continuation, or not being obtainable at all. That is claim 55unconfirmed resolving against. Without it there is no budget line to sell into.

Assumption register

Four new assumptions, each with what would settle it and who could run it. They were appended to the candidate as unverified claims 56–59 before this file was written. A1 is claim 56unverified, with jurisdiction: DE. A2–A4 are claims 57–59, with jurisdiction: US.

The previous build's twelve assumptions were written back as claims 44–55, and the Verifier attempted all of them on 2026-09-29. All came back unconfirmed. They are cited above as claims and not re-declared, because a figure travels as the claim that recorded it.

#	Assumption	Falsifier	Owner
A1	In Germany, a point-of-care potassium and creatinine test run by an outpatient cardiology or nephrology practice is paid to that practice within an existing statutory ambulatory laboratory fee position (EBM chapter 32), so no new-method assessment is needed before statutory insurers pay	A human reading the current EBM laboratory chapter and its rules on practice-performed tests. A single case where such a test needs a separate G-BA method assessment, or cannot be billed by the performing practice, would settle it against. No connector reaches a non-US payment system, so this cannot be closed inside the pipeline	Ex-US reimbursement analyst
A2	A material share of the target US outpatient HF and nephrology clinics are physician-office sites billing potassium and creatinine to Part B on their own CLIA certificate, rather than hospital-owned provider-based departments billing on the hospital's institutional claim	CMS (Centers for Medicare & Medicaid Services) Provider of Services and CLIA laboratory files cross-referenced to cardiology and nephrology practice locations, splitting sites into independent physician-office labs and hospital-owned departments. Then `apc 84132` once `data/opps_addendum_b.csv` exists, for how the hospital-department share is paid	Reimbursement analyst
A3	Medicare Advantage and commercial payers pay a physician-office laboratory for 84132 and 82565 at or above the Medicare CLFS national limitation amounts	Negotiated rates for the two codes from payer Transparency-in-Coverage machine-readable files, for three large commercial plans and two MA (Medicare Advantage) plans in two target states. Any plan paying below the CLFS amounts lowers the ceiling in the money model	Reimbursement analyst
A4	A majority of US outpatient cardiology and nephrology practices that placed a point-of-care chemistry analyzer capable of potassium testing were still running potassium on it in-house twelve months after placement	Reagent reorder data for potassium-capable point-of-care cartridges or rotors at cardiology and nephrology accounts, from a distributor or a willing incumbent, at months three and twelve after placement, with the stated reason for any lapse. This is revealed behaviour, and it replaces asking clinics whether they would switch	Commercial / business development

Where this case outruns the file

Every figure with no claim behind it, gathered as work items.

The cost side of the one inequality that decides Route A. Strip cost of goods, meter amortisation, QC material and operator time per paired result appear nowhere in the file. claim 36unconfirmed states the question, and the verified CLFS rate is only its other half.
Non-Medicare payment (A3). Every payment figure on this page is Medicare fee-for-service. The HF/CKD population is heavily Medicare-age, but that says nothing about how much of it is in Medicare Advantage, and no claim speaks to commercial rates.
Site-of-care mix (A2). The verified volume file cannot see hospital-outpatient institutional claims. So it cannot say whether the target clinics are offices that bill themselves or hospital departments that do not.
Retention after placement (A4). Nothing in the file says whether clinics that have had a point-of-care potassium option kept using it. That is the observable version of the switching question claim 49unconfirmed.
Germany and the UK (A1). The file's launch_jurisdiction: is US. The German assumption is new with this build, and nothing speaks to the UK in either direction.
The size of anything. There is no market model, and this case builds no size in its place. The Medicare service counts are verified, but the file itself says they must not be multiplied into a market claim 16verified. The share figure that would turn them into one is the Generator's own assumption over an uncounted denominator claim 18unconfirmed, claim 35unconfirmed.
Calendar and capital to first dollar. The candidate declines to put a number on either, on the correct ground that any number would be invented claim 26unconfirmed, claim 50unconfirmed, claim 51unconfirmed.

Words on this page20 abbreviation(s) and code(s), with what each stands for — copied from _shared/plain-language.md

21 CFR: Title 21 of the Code of Federal Regulations — the US food-and-drug rulebook; a number after it is one regulation, often the one that classifies a device type
510(k): premarket notification — the FDA route for a device shown to be as safe and effective as one already on the market; months, no clinical trial as a rule
Class II: FDA device class II — moderate-risk devices, usually cleared by 510(k)
CLFS: clinical laboratory fee schedule — the Medicare price list for laboratory tests
CLIA: Clinical Laboratory Improvement Amendments — the US rules a clinical laboratory must meet to report test results on patients
CMS: Centers for Medicare & Medicaid Services — the US agency that runs Medicare, and so decides what Medicare pays for
CPT: Current Procedural Terminology — the US billing codes for what a clinician does; owned by the American Medical Association
FDA: US Food and Drug Administration — the US regulator that clears or approves a device before it can be sold
FFS: fee-for-service — the traditional form of Medicare that pays per item or service
FTO: freedom to operate — whether a product can be sold without infringing someone else's live patent
HCPCS: Healthcare Common Procedure Coding System — the US billing codes for equipment, supplies and some services; a code is how a payer recognises what to pay for
IP: intellectual property — patents and the other rights that let a company stop others copying it
K######: an FDA 510(k) clearance number — the public record of one cleared device; the letter K and six digits
MA: Medicare Advantage — Medicare delivered through a private insurer; must cover at least what Medicare covers
Medicare Advantage: Medicare Advantage — Medicare delivered through a private insurer; must cover at least what Medicare covers
NCD: national coverage determination — a Medicare rule, valid everywhere in the US, saying whether and when something is covered
NICE: National Institute for Health and Care Excellence — the English body whose guidelines say what the NHS should use
PFS: physician fee schedule — the Medicare price list for what clinicians do
QC: quality control — the samples and checks a laboratory runs to prove its test is still working
RVU: relative value unit — the unit Medicare uses to price a clinician's work

Generated from knowledge-base/commercial/idea-010.md by engine/scripts/build_review.py on 2026-10-04. This page is a view — edit the source file and rebuild, never edit here.